Opexa Therapeutics Inc. opxa stock (OPAL) is fresh off the heels of an announcement of February 7, 2013, units containing shares and warrants average shares of its common stock for $ 3/unit in goal of raising $ 3,250,000 is. $ 3250000 will go to Phase b study of Celina additional clinical and general corporate purposes. Celina is intended to treat patients with opxa stock secondary progressive MS. Supply is expected to occur on or about February 11.
Opexa trading at a very fast pace, with an average volume of Y2K 3 months, but it has increased a lot recently, and traded at 1.5 m in the last ten days or more. That comes from a large 9.8 million shares traded opxa stock, on February 5. The short interest declined steadily OPAL in 2012 the stock has slipped by a high fence of $ 4.12 last February in a much lower $ 1.20 on January 31 this year. Days to cover short interest declined steadily throughout 2012.
So soon i will writ more article about opxa stock.
But now, with the sudden rise in the price, will be curious to see the interest gets short report on this stock in the near future. Another interesting part of the recent news that has flown quietly under the radar is a bit of a remodel in institutional holdings. The latest report on nasdaq.com showed that opxa stock only 5 % of the shares were held by institutional investors.
No comments:
Post a Comment